You are leaving our website

or Decline

Result of General Meeting


("Alliance" or the "Group")

Alliance Pharma plc (AIM: APH) ("Alliance" or the "Company"), the speciality pharmaceutical company, is pleased to announce that, in connection with the proposed acquisition of the Healthcare Products Business from Sinclair IS Pharma plc (the "Acquisition") and the placing to part fund the Acquisition (the "Placing") announced by the Company on 26 November 2015, all resolutions put to shareholders at the General Meeting today were duly passed.

Completion of the Acquisition and Placing ("Completion") and re-admission of the Company's enlarged issued share capital to trading on AIM ("Re-Admission") are expected to take place at 8.00am on 17 December 2015. Following Completion and Re-admission the Company's issued ordinary share capital will be 468,179,146 ordinary shares.

Issued share capital at Re-Admission

The Company's enlarged issued share capital of 468,179,146 shares includes an existing issued share capital of 264,520,611 ordinary shares and not 264,520,610 shares as had been incorrectly stated in the Company's RNS announcement and Admission Document relating to the Acquisition and Placing, dated 26 November 2015.

A reconciliation of the Company's current issued share capital to the number of shares that the Company has admitted to trading, demonstrated that a total of 1,269,296 shares have been issued and allotted by the Company historically but have not been admitted to trading on AIM, as a result of an administrative oversight. Consequently, an application has been made for these 1,269,296 shares, which are included in the Company's existing issued share capital figure of 264,520,611, to be admitted to trading on AIM. Admission of these 1,269,296 shares is expected to take place at 8.00am on 17 December 2015, such that the enlarged issued share capital of the Company at completion will be 468,179,146 ordinary shares, as stated above.

The above figure of 468,179,146 shares may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.

For further information:

Alliance Pharma plc + 44 (0)1249 466966
Peter Butterfield, Chief Executive Officer
Andrew Franklin, Chief Financial Officer

Buchanan + 44 (0)20 7466 5000
Mark Court / Sophie Wills / Hannah Ratcliff

Numis Securities Limited + 44 (0)20 7260 1000
Nominated Adviser: Michael Meade / Freddie Barnfield
Corporate Broking: James Black

Investec Bank plc + 44 (0)20 7597 5970
Corporate Finance: Daniel Adams / Ed Thomas
Corporate Broking: Patrick Robb / Tejas Padalkar